Shanghai United Imaging Healthcare (688271) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was RMB 1.62 billion, down 25% year-over-year; YTD revenue reached RMB 6.95 billion, down 6.43% year-over-year.

• Net loss attributable to shareholders in Q3 was RMB 279 million, a decline of 320.57% year-over-year; YTD net profit was RMB 671 million, down 36.94%.

• Excluding non-recurring items, Q3 net loss was RMB 334 million, down 899.46% year-over-year; YTD adjusted net profit was RMB 464 million, down 44%.

Financial highlights

• Basic and diluted EPS for Q3 were -0.34 RMB, down 326.67% year-over-year; YTD EPS was 0.82 RMB, down 36.43%.

• Gross margin for the first nine months was 49.4%, slightly down from 51.4% a year ago.

• Operating cash flow for the first nine months was negative RMB 1.50 billion, mainly due to lower revenue and collections.

• R&D investment in Q3 was RMB 618 million, up 20.03% year-over-year; YTD R&D was RMB 1.63 billion, up 14.32%.

• R&D spending accounted for 38.11% of Q3 revenue, up 14.3 percentage points year-over-year.

Outlook and guidance

• Management attributes profit decline to a softer market environment and increased investment in overseas expansion and sales.

• R&D and sales expenses are expected to remain elevated as the company continues to invest in growth.